172 related articles for article (PubMed ID: 34913153)
1. Quality-of-Life Outcomes, Effectiveness and Tolerability of Apremilast in Patients with Plaque Psoriasis and Routine German Dermatology Care: Results from LAPIS-PSO.
Reich K; Korge B; Magnolo N; Manasterski M; Schwichtenberg U; Staubach-Renz P; Kaiser S; Roemmler-Zehrer J; Gómez NN; Lorenz-Baath K
Dermatol Ther (Heidelb); 2022 Jan; 12(1):203-221. PubMed ID: 34913153
[TBL] [Abstract][Full Text] [Related]
2. Improved Quality of Life in Patients with Psoriasis Receiving Apremilast: Real-World Data from the Netherlands.
van den Reek JMPA; van der Leest RJT; Thomas SE; Prevoo R; Plantenga ME; de Jong EMGJ
Adv Ther; 2024 Apr; 41(4):1594-1605. PubMed ID: 38402373
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of apremilast in biologic-naïve patients with moderate psoriasis treated in routine clinical practice in Greece: the APRAISAL study.
Ioannides D; Antonakopoulos N; Georgiou S; Chasapi V; Katsantonis I; Drosos A; Rigopoulos D; Antoniou C; Anastasiadis G; Bassukas I; Ioannidou D; Protopapa A; Neofotistou O; Krasagakis K; Aronis P; Papageorgiou M; Lazaridou E; Patsatsi A; Lefaki I; Roussaki-Schulze AV; Satra F; Anagnostopoulos Z; Papakonstantis M
J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):1838-1848. PubMed ID: 34036627
[TBL] [Abstract][Full Text] [Related]
4. Real-World Apremilast Use for Treatment of Plaque Psoriasis in Italy: Patient Perspective, Characteristics, and Clinical Outcomes from the DARWIN Study.
Giofrè C; Fabbrocini G; Potenza C; Tiberio R; Gisondi P; Marasca C; Nuzzo CMA; Benincasa E; Bianchi L;
Adv Ther; 2023 Jul; 40(7):3021-3037. PubMed ID: 37171752
[TBL] [Abstract][Full Text] [Related]
5. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis.
Papadavid E; Rompoti N; Theodoropoulos K; Kokkalis G; Rigopoulos D
J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):1173-1179. PubMed ID: 29388335
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of apremilast in the treatment of plaques psoriasis: A real-world, single-center experience.
Radi G; Campanati A; Diotallevi F; Rizzetto G; Martina E; Bobyr I; Giannoni M; Offidani A
Dermatol Ther; 2021 Nov; 34(6):e15179. PubMed ID: 34704350
[TBL] [Abstract][Full Text] [Related]
8. Association Between Patient- and Physician-Reported Outcomes in Patients with Moderate-To-Severe Plaque Psoriasis Treated with Biologics in Real Life (PSO-BIO-REAL).
Lacour JP; Bewley A; Hammond E; Hansen JB; Horne L; Paul C; Reich K; Seneschal J; De Simone C; Sohrt A; Augustin M; Pellacani G
Dermatol Ther (Heidelb); 2020 Oct; 10(5):1099-1109. PubMed ID: 32761560
[TBL] [Abstract][Full Text] [Related]
9. The Needs of Patients with Psoriasis and Benefits of Apremilast in French Clinical Practice: Results from the Observational REALIZE Study.
Jullien D; Richard MA; Halioua B; Bessette C; Derancourt C; Bouloc A
Dermatol Ther (Heidelb); 2023 Jun; 13(6):1361-1376. PubMed ID: 37204608
[TBL] [Abstract][Full Text] [Related]
10. Real-Life Effectiveness of Apremilast for the Treatment of Psoriasis in Belgium: Results From the Observational OTELO Study.
Ghislain PD; Lambert J; Lam Hoai XL; Hillary T; Roquet-Gravy PP; de la Brassinne M; Segaert S
Adv Ther; 2022 Feb; 39(2):1068-1080. PubMed ID: 34977985
[TBL] [Abstract][Full Text] [Related]
11. Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.
Thaçi D; Strober B; Gordon KB; Foley P; Gooderham M; Morita A; Papp KA; Puig L; Menter MA; Colombo MJ; Elbez Y; Kisa RM; Ye J; Napoli AA; Wei L; Banerjee S; Merola JF; Gottlieb AB
Dermatol Ther (Heidelb); 2022 Feb; 12(2):495-510. PubMed ID: 35025062
[TBL] [Abstract][Full Text] [Related]
12. Safety and effectiveness of apremilast in Japanese patients with psoriatic disease: Results of a post-marketing surveillance study.
Ohtsuki M; Okubo Y; Saeki H; Igarashi A; Imafuku S; Abe M; Chaudhari S; Yaguchi M; Emoto A; Morita A
J Dermatol; 2024 May; ():. PubMed ID: 38775204
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL.
Stein Gold L; Bagel J; Lebwohl M; Jackson JM; Chen R; Goncalves J; Levi E; Duffin KC
J Drugs Dermatol; 2018 Feb; 17(2):221-228. PubMed ID: 29462231
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of apremilast in patients with limited skin involvement, plaque psoriasis in special areas and impaired quality of life: Results from the EMBRACE randomized trial.
Mrowietz U; Barker J; Conrad C; Jullien D; Gisondi P; Flower A; Reddy J; Paris M; Picard H; Jardon S; Augustin M
J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):348-355. PubMed ID: 36300769
[TBL] [Abstract][Full Text] [Related]
15. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study.
Van Voorhees AS; Stein Gold L; Lebwohl M; Strober B; Lynde C; Tyring S; Cauthen A; Sofen H; Zhang Z; Paris M; Wang Y
J Am Acad Dermatol; 2020 Jul; 83(1):96-103. PubMed ID: 32032692
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, tolerability and patient's satisfaction for the treatment of moderate to severe plaque psoriasis with apremilast in the real-life setting of Campania region, Italy.
Licata G; Tancredi V; Gambardella A; Megna M; Fabbrocini G; Raimondo A; Lembo S; Ligrone L; Cusano F; Argenziano G
Ital J Dermatol Venerol; 2023 Dec; 158(6):452-456. PubMed ID: 37721774
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
Qiu J; Liu J; Liu W; Lin F; Shi N
Front Med (Lausanne); 2023; 10():1264667. PubMed ID: 37841017
[TBL] [Abstract][Full Text] [Related]
19. A real-world, non-interventional, prospective study of the effectiveness and safety of apremilast in bio-naïve adults with moderate plaque psoriasis treated in the routine care in Greece - the 'APRAISAL' study.
Ioannides D; Antonakopoulos N; Chasapi V; Oikonomou C; Tampouratzi E; Lazaridou E; Rigopoulos D; Neofotistou O; Drosos A; Anastasiadis G; Rovithi E; Kalinou C; Papadavid E; Aronis P; Papageorgiou M; Protopapa A; Bassukas I; Lefaki I; Zafiriou E; Krasagakis K; Pokas E; Anagnostopoulos Z; Kekki A; Papakonstantis M
J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2055-2063. PubMed ID: 35451115
[TBL] [Abstract][Full Text] [Related]
20. Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc Analysis.
Armstrong AW; Park SH; Patel V; Nicolas P; Wang WJ; Colombo MJ; Chirikov V
Dermatol Ther (Heidelb); 2024 Jun; ():. PubMed ID: 38907877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
